If you’ve been following the smart money disclosures this earnings season, you know the drill: hedge funds zig, mutual funds zag, and everyone tries to figure out if the AI trade is finally over. But when it comes to Cathie Wood and ARK Invest, the narrative is never that simple.
The Cathie Wood latest 13F filing for Q4 2025 just dropped, and let’s just say the "Queen of Innovation" isn’t sitting on her hands. The headline numbers? She is aggressively taking profits on her golden geese—Tesla and Palantir—and redeploying that capital into what looks like a high-conviction bet on the next generation of crypto infrastructure and genomic medicine.
We broke down the visual data from the latest portfolio map to see exactly where the money is flowing. Here is the deep dive into ARK’s latest shake-up.
The Big Trim: Taking Profits on the Winners
For years, Tesla (TSLA) has been the sun around which the ARK universe orbits. It’s still the top holding at 8.7% of the portfolio, but the Q4 moves tell a story of caution—or perhaps just disciplined rebalancing. Wood slashed the Tesla position by a staggering 18.81% (shedding over 675,000 shares).
When you see a trim that size on a high-conviction name, it usually signals one of two things: valuation concerns or a desperate need for cash to fund new ideas. Considering Shopify (SHOP) and Roku (ROKU) faced even steeper cuts—down 17.38% and 20.00% respectively—it looks like a broader sector rotation.
The most surprising exit for many retail investors will be Palantir (PLTR). After a banner year for the data analytics giant, ARK sold nearly 20% of its stake. This isn't a complete exit, as it remains a top-five holding, but it’s a clear signal that ARK believes the easy money in "established" AI software might have already been made.
Crypto Infrastructure: The New "High Beta" Play
If the capital is leaving the SaaS and EV giants, where is it going? Look no further than the blockchain plumbing.
While Bitcoin price action grabs the headlines, ARK’s Q4 buying spree was focused on the companies building the rails. Coinbase (COIN) saw a healthy 6.11% boost, solidifying its place as a core pillar of the fund. But the real eyebrow-raiser is Circle.
ARK increased its stake in Circle by a massive 39.59%. This is a specific bet on the proliferation of stablecoins and digital payments rather than just speculative token trading. It suggests a thesis where crypto becomes boringly transactional—which is exactly when it becomes profitable for infrastructure plays.
Rounding out this theme is a 26.61% increase in Bitmine Immersion Technologies. This is a deeper cut, a small-cap play on the energy efficiency of mining. By moving into the hardware and cooling side of the industry, Wood is betting that the energy demands of crypto (and likely AI data centers) will make thermal management a massive growth sector.
The Biotech Renaissance
Biotech has been a "widow-maker" trade for the better part of three years, but Wood is doubling down. The data shows a cluster of aggressive buying in the gene-editing space.
-
CRISPR Therapeutics (CRSP): + 7.51%.
-
Beam Therapeutics (BEAM): + 12.94%.
-
Twist Bioscience (TWST): + 12.38%.
This is classic ARK: buying the dip in a beaten-down sector with massive theoretical upside. The "network effect" here is undeniable—Twist provides the synthetic DNA that companies like Ginkgo (not pictured but often correlated) and various researchers use, while CRISPR and Beam are racing toward commercial therapies. By buying the basket, ARK is effectively indexing the future of personalized medicine.
The Chip War: Nvidia vs. AMD
Perhaps the most tactical shift in the portfolio is in the semiconductor space. For a while, the contrarian trade was to buy AMD as the "catch-up" play to Nvidia. Wood seems to have thrown in the towel on that specific thesis.
The fund dumped 15.80% of its AMD shares while adding 7.63% to its Nvidia position and inching up TSMC (+0.88%). This suggests a flight to quality. In the AI hardware arms race, the market leader (Nvidia) and the manufacturer (TSMC) are being viewed as safer bets than the challenger (AMD), despite the valuation premiums.
Frontier Tech: Flying Cars and AI Doctors
Finally, we have to look at the "Collective High-Growth Bets" that make up the long tail of the portfolio.
Archer Aviation (ACHR) saw a 12.36% position increase. With eVTOL (electric vertical takeoff and landing) regulatory timelines becoming clearer in late 2025, this is a binary bet: either they get certified and change urban mobility, or they go to zero. Wood is clearly betting on the former.
Similarly, Tempus AI saw a 5.32% bump. Sitting at the intersection of AI and healthcare data, Tempus fits the ARK mold perfectly. It’s less about "generative AI" for writing emails and more about using large models to analyze clinical data—a use case that is harder to monetize but has a significantly deeper moat.
The Takeaway
Selling Tesla and Palantir—stocks that arguably made Cathie Wood famous—to fund bets on stablecoins, gene editing, and flying cars is a bold strategy. It signals that ARK believes the "Magnificent 7" era of tech dominance is transitioning into a new phase where the winners will be the companies building the physical and financial infrastructure of the future, not just the software platforms of the present.